Clinical Data GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail BioSpaceCamlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, "is unlikely to transform patient care," the pharma said.RespiratoryRead full story pharminent July 17, 2026 (Last updated: July 20, 2026) BioSpace Camlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said. Respiratory Read full story Post navigation Previous: FDA grants traditional approval to Novartis’ Fabhalta for IgANNext: Novo Lands European Oral Wegovy Approval Before Lilly Can Respond Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
